Targeting the microtubules in breast cancer beyond taxanes: the epothilones
- PMID: 17405891
- DOI: 10.1634/theoncologist.12-3-271
Targeting the microtubules in breast cancer beyond taxanes: the epothilones
Abstract
Microtubule-targeting agents such as the taxanes are highly active against breast cancer and have become a cornerstone in the treatment of patients with early and advanced breast cancer. The natural epothilones and their analogs are a novel class of microtubule-stabilizing agents that bind tubulin and result in apoptotic cell death. Among this family of compounds, patupilone, ixabepilone, BMS-310705, ZK-EPO, and KOS-862 are in clinical development. Extensive preclinical studies have shown that epothilones are working through partially nonoverlapping mechanisms of action with taxanes. In the clinic, epothilones have been found in a series of phase I and phase II studies to be active even in patients who had recently progressed to taxanes. The toxicity profile of these agents consists mostly of sensory neuropathy, sometimes reversible. Neoadjuvant studies with epothilones have been conducted and a number of phase III studies in advanced breast cancer are either under way or have been recently completed. The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer.
Similar articles
-
Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.Clin Adv Hematol Oncol. 2009 Feb;7(2):115-22. Clin Adv Hematol Oncol. 2009. PMID: 19367253
-
The epothilones: how pharmacology relates to clinical utility.Ann Pharmacother. 2009 Jul;43(7):1294-309. doi: 10.1345/aph.1M005. Epub 2009 Jul 7. Ann Pharmacother. 2009. PMID: 19584389 Review.
-
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.Clin Breast Cancer. 2008 Dec;8 Suppl 4:S166-70. doi: 10.3816/CBC.2008.s.013. Clin Breast Cancer. 2008. PMID: 19158037 Review.
-
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.Future Oncol. 2008 Aug;4(4):483-500. doi: 10.2217/14796694.4.4.483. Future Oncol. 2008. PMID: 18684060 Review.
-
Preclinical discovery of ixabepilone, a highly active antineoplastic agent.Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Cancer Chemother Pharmacol. 2008. PMID: 18347795 Review.
Cited by
-
Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.Acta Neuropathol Commun. 2016 Sep 29;4(1):106. doi: 10.1186/s40478-016-0378-4. Acta Neuropathol Commun. 2016. PMID: 27687527 Free PMC article.
-
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.J Neurosci. 2012 Mar 14;32(11):3601-11. doi: 10.1523/JNEUROSCI.4922-11.2012. J Neurosci. 2012. PMID: 22423084 Free PMC article.
-
Novel microtubule-targeting agents - the epothilones.Biologics. 2008 Dec;2(4):789-811. doi: 10.2147/btt.s3487. Biologics. 2008. PMID: 19707459 Free PMC article.
-
Management of advanced breast cancer with the epothilone B analog, ixabepilone.Drug Des Devel Ther. 2009 Sep 21;3:163-71. doi: 10.2147/dddt.s3122. Drug Des Devel Ther. 2009. PMID: 19920932 Free PMC article.
-
Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.Mol Cancer Ther. 2010 Nov;9(11):2970-81. doi: 10.1158/1535-7163.MCT-10-0780. Epub 2010 Nov 9. Mol Cancer Ther. 2010. PMID: 21062914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
